ProCE Banner Activity

The Value of Interactive Tools in Selecting Treatment for CLL

Clinical Thought

In this commentary, learn how interactive treatment decision support tools can positively impact therapeutic choices for patients with CLL, and link to CCO’s latest expert-led tool.

Released: October 28, 2024

Expiration: October 27, 2025

Share

Faculty

Nicole Lamanna

Nicole Lamanna, MD

Judy Horrigan Professor of Medicine, Leukemia Service
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
NewYork-Presbyterian/Columbia University Medical Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC in partnership with CLL Society

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc.; AstraZeneca; Beigene, Ltd.; and Bristol Myers Squibb.

AbbVie Inc.

AstraZeneca

BeiGene, Ltd.

Bristol Myers Squibb

Partners

CLL Society

ProCE Banner

Disclosure

Primary Author

Nicole Lamanna, MD

Judy Horrigan Professor of Medicine, Leukemia Service
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
NewYork-Presbyterian/Columbia University Medical Center
New York, New York

Nicole Lamanna, MD: consultant/advisor/speaker: AbbVie, Adaptive Biosciences, Allogene Therapeutics, AstraZeneca, BeiGene, Genentech, Genmab, Lilly/Loxo, Pharmacyclis/Janssen; researcher (paid to institution): AbbVie, AstraZeneca, BeiGene, Genentech, Genmab, Loxo/Lilly, MingSight, Octapharma, Oncternal.